Merck & Company (MRK) 60.08 $MRK
US Cancer Vaccine Pipeline Analysis
M2 - 1 hr 59 mins ago
Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. Merck's Gardasil, a Prophylactic cancer vaccine, along with GSK's Cervarix are some of the first vaccines to have gained attention globally with their blockbuster status.
Merck & Co., Inc. Wins First Stage of the PD-1 Race
Brian Orelli, The Motley Fool - Motley Fool - Thu Sep 04, 9:55PM CDT
Source: Merck. Merck has won the race to get the first immunotherapy drug that blocks the PD-1 pathway on the U.S. market. Today, the FDA approved pembrolizumab, which will go by the brand name Keytruda, for patients with advanced or...
FDA OKs Merck drug, 1st in new cancer drug class
By LINDA A. JOHNSON - AP - Thu Sep 04, 4:41PM CDT
TRENTON, N.J. (AP) — Merck & Co. on Thursday won the first U.S. approval for a new kind of cancer drug with big advantages over chemotherapy and other older cancer treatments.
FDA Approves Pembrolizumab for Advanced Melanoma
PR Newswire - Thu Sep 04, 4:07PM CDT
Today the FDA approved Keytruda (pembrolizumab), a new treatment for advanced melanoma, the deadliest form of skin cancer. Melanoma patients have been waiting anxiously for this day, given the promising data that early studies have shown. In clinical trials, 24 percent of patients taking pembrolizumab had their tumors shrink. Most of these patients continued to respond past the 8.5 month study cut off. This is particularly significant because these studies were conducted in patients who had already failed to respond to other approved therapies. The approval of pembrolizumab is a tremendous step forward for the melanoma patient community, as this is the most promising and positive patient response to a melanoma treatment to date.
Merck PD-1 Inhibitor Approved For Skin Cancer
at Investor's Business Daily - Thu Sep 04, 3:33PM CDT
Merck's (MRK) pembrolizumab won FDA approval for melanoma Thursday afternoon, making it the first drug in the much-anticipated PD-1 inhibitor class to hit the U.S. market. Pembrolizumab, now branded Keytruda, was approved before the normal three...
Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy
PR Newswire - Thu Sep 04, 2:46PM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
How Will Merck (MRK) Stock React To FDA Approval Of Melanoma Immunotherapy?
at The Street - Thu Sep 04, 2:40PM CDT
Merck (MRK) won FDA approval to bring to market the first in a new line of cancer fighting treatments that use patients' own immune systems against the disease.
MRA Applauds Latest Melanoma Drug Approval as "Major Breakthrough"
Business Wire - Thu Sep 04, 2:31PM CDT
The Melanoma Research Alliance (MRA) today welcomed as a major breakthrough the news that the U.S. Food & Drug Administration (FDA) has granted approval to Merck's new immunotherapy drug, Keytruda (pembrolizumab), for treating metastatic melanoma. It is the first anti-PD-1 drug, aimed at re-energizing a patient's protective immune response to cancer, to have earned FDA approval in the U.S.
Merck Receives Accelerated Approval of KEYTRUDA(R) (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy
Business Wire - Thu Sep 04, 2:15PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA(R) (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Merck Skin Cancer Immunotherapy Gets FDA Approval
at The Street - Thu Sep 04, 1:36PM CDT
Merck will sell the skin cancer drug under the brand name Keytruda.
Dow Today: Merck (MRK) Higher
at The Street - Thu Sep 04, 1:30PM CDT
The Dow component leading the way higher looks to be Merck (NYSE:MRK), which is sporting a three-cent gain to $60.51.
Global Intranasal Drug Delivery Market & Pipeline Insight 2014: Powder, Gels, Liquid & Pressurized MDI
M2 - Thu Sep 04, 9:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5232vq/global_intranasal) has announced the addition of the "Global Intranasal Drug Delivery Market & Pipeline Insight" report to their offering. Intranasal drug delivery has evolved in the recent years as a significant method of delivering drugs through the nasal route. This method has been identified to have all the potential to achieve significant milestones in the pharmaceutical industry, as it is largely driven by its capability to cure local infections and chronic allergies. The human nose, which has a unique vascular structure, makes it specifically accessible for delivering small molecule drugs and biologics. By taking advantage of the conducive healthcare trends and changing demography, the intranasal drug delivery route is likely to capture the popularity of other leading methods of drug delivery such as oral and parenteral. The use of nasal sprays and inhalers has had a great impact in improving the drug administration experience, enhancing compliance rates, and ensuring safety. These systems have emerged as a segment with huge potential for the future and are playing an increasingly prominent role in a range of competitive intranasal devices markets. The growth and competitiveness of the intranasal drugs and devices market has led to the extensive development and innovation of new and nth-generation devices which have the capacity to overcome the limitations of the previous drug delivery technologies. With an increasing number of patients preferring to use self-administering devices like sprays and inhalers to avoid the pain, the market for these products is likely to grow at a substantial rate in the near future. This increasing demand is also having a great impact in terms of attracting new companies into the market. The future years are expected to witness a steady increase in chronic diseases, if not a rapid increase and this is also a major driver of intranasal drug delivery technologies. The intranasal drug delivery market is likely to witness more developments in formulation techniques, like improvised micro-encapsulation techniques, more use of muco adhesive and surfactant agents and nanotechnology. This would in turn lead to an increased number of new chemical entities which could possibly be considered as the active ingredients for future intranasal drug products. Similarly, it is also expected that modern approaches to vaccination would be increasingly used which could also generate a wide range of new prophylactic and therapeutic products which would be appropriate for delivery through the nasal route. Key Topics Covered: 1. Introduction to Intranasal Drug Delivery 2. Intranasal Drug Delivery Mechanism 3. Need for Intranasal Drug Delivery 4. Applications of Intranasal Drug Delivery 5. Intranasal Drug Delivery Market Overview 6. Intranasal Drug Delivery Market Dynamics 7. Intranasal Drug Delivery Market Future Outlook 8. Intranasal Drug Clinical Pipeline by Indication, Phase, Company & Country 9. Marketed Intranasal Drugs by Indication, Company & Country 10. Suspended & Discontinued Intranasal Drugs in Clinical Pipeline by Indication, Phase, Company & Country 11. Competitive Landscape - Aegis Therapeutics - Archimedes Pharma - GlaxoSmithKline - MEDA AB - MedImmune - Merck - NanoBio Corporation - Novartis - OptiNose - Pherin Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/52...intranasal
Is it Time to Buy Merck & Co., Inc.'s Stock?
Sean Williams, The Motley Fool - Motley Fool - Thu Sep 04, 8:47AM CDT
Investors in pharmaceutical giant Merck have to be liking what they've witnessed in recent years as Merck's stock has vaulted to its highest levels since prior to the Great Recession. However, back Merck's chart out to a 15-year view and things...
Merck's Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA
Business Wire - Thu Sep 04, 8:01AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated relebactam (previously known as MK-7655), the company's investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product (QIDP) with designated Fast Track status. The QIDP and Fast Track designations apply to intravenous use of relebactam for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia.
3 Reasons GlaxoSmithKline's Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Thu Sep 04, 7:20AM CDT
Big pharmas have been a mixed bag this year in terms of the performance of their stock prices. Some companies like Merck & Co . have seen their stock prices soar as their reorganization and clinical efforts have helped to turn the tide against...
SmarTrend Watching for Potential Pullback in Shares of Merck After 1.15% Gain
Comtex SmarTrend(R) - Wed Sep 03, 3:42PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $60.06 to a high of $60.86. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $60.42 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 1.15% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Sep 03, 3:41PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $60.06 to a high of $60.86. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $60.42 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Dow Today: Merck (MRK) Leads The Day Higher, Caterpillar (CAT) Lags
at The Street - Wed Sep 03, 3:30PM CDT
The Dow component that led the way higher today was Merck (NYSE:MRK), which sported a 69-cent gain (+1.1%) bringing the stock to $60.48. Holding the Dow back today was Caterpillar (NYSE:CAT), which lagged the broader Dow index with a 46-cent decline...
Tetraphase (TTPH) Up on IGNITE 2 Results on Eravacycline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 12:13PM CDT
Shares of Tetraphase Pharmaceuticals, Inc. (TTPH) were up as the company reported positive top-line results on its lead pipeline candidate, eravacycline.
Global Anti-Coccidial Drugs Market In Animal Health - Global Trends And Forecasts 2014-19
M2 - Wed Sep 03, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snk76v/global) has announced the addition of the "Global Anti-Coccidial Drugs Market In Animal Health - Global Trends And Forecasts - (2014-19)" report to their offering. The increase in global population and also in the per capita global consumption of meat, the increased adoption of intensive farming methods is estimated to drive the market for anticoccidials to $24.33 billion by the year 2020. The Asia pacific region is set to be the highest contributor in terms of total revenue in this market by the year 2020. The countries set to be major contributors from this region are China, India, Japan, Australia etc. The growth in the North American and European markets is set to be stagnant due to the stagnated market and government restrictions. In the veterinary antibiotic market the market for food producing animals account for nearly 80 % of the total market in 2011 this has increased the demand for anticoccidial drugs, largely due to the increased incidences of coccidiosis and other protozoan parasite based diseases that infects majorly food producing organism but are not limited to them. In poultry and cattle markets the incidence of coccidiosis has cost the millions of dollars in treatment and preventive care being given. Also the trend of owning companion animals is also contributing to the increasing use of anitcoccidials, as dogs , cats and occasionally even horses are prone to coccidiosis and if left untreated it could lead to the death of the animal The Market research report titled Global Anticoccidial market- Analysis and future forecast' categorizes the global anticoccidial market on the basis of animal type and geography; forecasting the revenues and analyzing the trends in each of the following submarkets. Key Topics Covered: 1. Introduction 2. Market Defenition 3. Market Drivers 4. Market Restraints 5. Market opportunities 6. Anti Coccidial drugs 7. Region wise analysis of anticoccidial market ( Market size, Forecast and CAGR) 8. Segmentation by Animal Type - anticoccidial market ( Market size, Forecast and CAGR) 9 The future of anticoccidial market 10 Competitive Landscape 11 Company Profiles - Zoetis - Elanco - Merial - Bayer Health care Animal Healthcare division - Merck Animal Healthcares - Boehringer Ingolheim Animal Health - Virbac - Novartis Animal Healthcare For more information visit http://www.researchandmarkets.com/research/snk76v/global
US Cancer Vaccine Pipeline Analysis
M2 - 1 hr 59 mins ago
Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. Merck's Gardasil, a Prophylactic cancer vaccine, along with GSK's Cervarix are some of the first vaccines to have gained attention globally with their blockbuster status.
Merck & Co., Inc. Wins First Stage of the PD-1 Race
Brian Orelli, The Motley Fool - Motley Fool - Thu Sep 04, 9:55PM CDT
Source: Merck. Merck has won the race to get the first immunotherapy drug that blocks the PD-1 pathway on the U.S. market. Today, the FDA approved pembrolizumab, which will go by the brand name Keytruda, for patients with advanced or...
FDA OKs Merck drug, 1st in new cancer drug class
By LINDA A. JOHNSON - AP - Thu Sep 04, 4:41PM CDT
TRENTON, N.J. (AP) — Merck & Co. on Thursday won the first U.S. approval for a new kind of cancer drug with big advantages over chemotherapy and other older cancer treatments.
FDA Approves Pembrolizumab for Advanced Melanoma
PR Newswire - Thu Sep 04, 4:07PM CDT
Today the FDA approved Keytruda (pembrolizumab), a new treatment for advanced melanoma, the deadliest form of skin cancer. Melanoma patients have been waiting anxiously for this day, given the promising data that early studies have shown. In clinical trials, 24 percent of patients taking pembrolizumab had their tumors shrink. Most of these patients continued to respond past the 8.5 month study cut off. This is particularly significant because these studies were conducted in patients who had already failed to respond to other approved therapies. The approval of pembrolizumab is a tremendous step forward for the melanoma patient community, as this is the most promising and positive patient response to a melanoma treatment to date.
Merck PD-1 Inhibitor Approved For Skin Cancer
at Investor's Business Daily - Thu Sep 04, 3:33PM CDT
Merck's (MRK) pembrolizumab won FDA approval for melanoma Thursday afternoon, making it the first drug in the much-anticipated PD-1 inhibitor class to hit the U.S. market. Pembrolizumab, now branded Keytruda, was approved before the normal three...
Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy
PR Newswire - Thu Sep 04, 2:46PM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
How Will Merck (MRK) Stock React To FDA Approval Of Melanoma Immunotherapy?
at The Street - Thu Sep 04, 2:40PM CDT
Merck (MRK) won FDA approval to bring to market the first in a new line of cancer fighting treatments that use patients' own immune systems against the disease.
MRA Applauds Latest Melanoma Drug Approval as "Major Breakthrough"
Business Wire - Thu Sep 04, 2:31PM CDT
The Melanoma Research Alliance (MRA) today welcomed as a major breakthrough the news that the U.S. Food & Drug Administration (FDA) has granted approval to Merck's new immunotherapy drug, Keytruda (pembrolizumab), for treating metastatic melanoma. It is the first anti-PD-1 drug, aimed at re-energizing a patient's protective immune response to cancer, to have earned FDA approval in the U.S.
Merck Receives Accelerated Approval of KEYTRUDA(R) (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy
Business Wire - Thu Sep 04, 2:15PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA(R) (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Merck Skin Cancer Immunotherapy Gets FDA Approval
at The Street - Thu Sep 04, 1:36PM CDT
Merck will sell the skin cancer drug under the brand name Keytruda.
Dow Today: Merck (MRK) Higher
at The Street - Thu Sep 04, 1:30PM CDT
The Dow component leading the way higher looks to be Merck (NYSE:MRK), which is sporting a three-cent gain to $60.51.
Global Intranasal Drug Delivery Market & Pipeline Insight 2014: Powder, Gels, Liquid & Pressurized MDI
M2 - Thu Sep 04, 9:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5232vq/global_intranasal) has announced the addition of the "Global Intranasal Drug Delivery Market & Pipeline Insight" report to their offering. Intranasal drug delivery has evolved in the recent years as a significant method of delivering drugs through the nasal route. This method has been identified to have all the potential to achieve significant milestones in the pharmaceutical industry, as it is largely driven by its capability to cure local infections and chronic allergies. The human nose, which has a unique vascular structure, makes it specifically accessible for delivering small molecule drugs and biologics. By taking advantage of the conducive healthcare trends and changing demography, the intranasal drug delivery route is likely to capture the popularity of other leading methods of drug delivery such as oral and parenteral. The use of nasal sprays and inhalers has had a great impact in improving the drug administration experience, enhancing compliance rates, and ensuring safety. These systems have emerged as a segment with huge potential for the future and are playing an increasingly prominent role in a range of competitive intranasal devices markets. The growth and competitiveness of the intranasal drugs and devices market has led to the extensive development and innovation of new and nth-generation devices which have the capacity to overcome the limitations of the previous drug delivery technologies. With an increasing number of patients preferring to use self-administering devices like sprays and inhalers to avoid the pain, the market for these products is likely to grow at a substantial rate in the near future. This increasing demand is also having a great impact in terms of attracting new companies into the market. The future years are expected to witness a steady increase in chronic diseases, if not a rapid increase and this is also a major driver of intranasal drug delivery technologies. The intranasal drug delivery market is likely to witness more developments in formulation techniques, like improvised micro-encapsulation techniques, more use of muco adhesive and surfactant agents and nanotechnology. This would in turn lead to an increased number of new chemical entities which could possibly be considered as the active ingredients for future intranasal drug products. Similarly, it is also expected that modern approaches to vaccination would be increasingly used which could also generate a wide range of new prophylactic and therapeutic products which would be appropriate for delivery through the nasal route. Key Topics Covered: 1. Introduction to Intranasal Drug Delivery 2. Intranasal Drug Delivery Mechanism 3. Need for Intranasal Drug Delivery 4. Applications of Intranasal Drug Delivery 5. Intranasal Drug Delivery Market Overview 6. Intranasal Drug Delivery Market Dynamics 7. Intranasal Drug Delivery Market Future Outlook 8. Intranasal Drug Clinical Pipeline by Indication, Phase, Company & Country 9. Marketed Intranasal Drugs by Indication, Company & Country 10. Suspended & Discontinued Intranasal Drugs in Clinical Pipeline by Indication, Phase, Company & Country 11. Competitive Landscape - Aegis Therapeutics - Archimedes Pharma - GlaxoSmithKline - MEDA AB - MedImmune - Merck - NanoBio Corporation - Novartis - OptiNose - Pherin Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/52...intranasal
Is it Time to Buy Merck & Co., Inc.'s Stock?
Sean Williams, The Motley Fool - Motley Fool - Thu Sep 04, 8:47AM CDT
Investors in pharmaceutical giant Merck have to be liking what they've witnessed in recent years as Merck's stock has vaulted to its highest levels since prior to the Great Recession. However, back Merck's chart out to a 15-year view and things...
Merck's Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA
Business Wire - Thu Sep 04, 8:01AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated relebactam (previously known as MK-7655), the company's investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product (QIDP) with designated Fast Track status. The QIDP and Fast Track designations apply to intravenous use of relebactam for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia.
3 Reasons GlaxoSmithKline's Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Thu Sep 04, 7:20AM CDT
Big pharmas have been a mixed bag this year in terms of the performance of their stock prices. Some companies like Merck & Co . have seen their stock prices soar as their reorganization and clinical efforts have helped to turn the tide against...
SmarTrend Watching for Potential Pullback in Shares of Merck After 1.15% Gain
Comtex SmarTrend(R) - Wed Sep 03, 3:42PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $60.06 to a high of $60.86. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $60.42 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 1.15% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Sep 03, 3:41PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $60.06 to a high of $60.86. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $60.42 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Dow Today: Merck (MRK) Leads The Day Higher, Caterpillar (CAT) Lags
at The Street - Wed Sep 03, 3:30PM CDT
The Dow component that led the way higher today was Merck (NYSE:MRK), which sported a 69-cent gain (+1.1%) bringing the stock to $60.48. Holding the Dow back today was Caterpillar (NYSE:CAT), which lagged the broader Dow index with a 46-cent decline...
Tetraphase (TTPH) Up on IGNITE 2 Results on Eravacycline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 12:13PM CDT
Shares of Tetraphase Pharmaceuticals, Inc. (TTPH) were up as the company reported positive top-line results on its lead pipeline candidate, eravacycline.
Global Anti-Coccidial Drugs Market In Animal Health - Global Trends And Forecasts 2014-19
M2 - Wed Sep 03, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snk76v/global) has announced the addition of the "Global Anti-Coccidial Drugs Market In Animal Health - Global Trends And Forecasts - (2014-19)" report to their offering. The increase in global population and also in the per capita global consumption of meat, the increased adoption of intensive farming methods is estimated to drive the market for anticoccidials to $24.33 billion by the year 2020. The Asia pacific region is set to be the highest contributor in terms of total revenue in this market by the year 2020. The countries set to be major contributors from this region are China, India, Japan, Australia etc. The growth in the North American and European markets is set to be stagnant due to the stagnated market and government restrictions. In the veterinary antibiotic market the market for food producing animals account for nearly 80 % of the total market in 2011 this has increased the demand for anticoccidial drugs, largely due to the increased incidences of coccidiosis and other protozoan parasite based diseases that infects majorly food producing organism but are not limited to them. In poultry and cattle markets the incidence of coccidiosis has cost the millions of dollars in treatment and preventive care being given. Also the trend of owning companion animals is also contributing to the increasing use of anitcoccidials, as dogs , cats and occasionally even horses are prone to coccidiosis and if left untreated it could lead to the death of the animal The Market research report titled Global Anticoccidial market- Analysis and future forecast' categorizes the global anticoccidial market on the basis of animal type and geography; forecasting the revenues and analyzing the trends in each of the following submarkets. Key Topics Covered: 1. Introduction 2. Market Defenition 3. Market Drivers 4. Market Restraints 5. Market opportunities 6. Anti Coccidial drugs 7. Region wise analysis of anticoccidial market ( Market size, Forecast and CAGR) 8. Segmentation by Animal Type - anticoccidial market ( Market size, Forecast and CAGR) 9 The future of anticoccidial market 10 Competitive Landscape 11 Company Profiles - Zoetis - Elanco - Merial - Bayer Health care Animal Healthcare division - Merck Animal Healthcares - Boehringer Ingolheim Animal Health - Virbac - Novartis Animal Healthcare For more information visit http://www.researchandmarkets.com/research/snk76v/global
